981 / 1084
The ToGA TRIAL: OS by HER-2 status
The cohort of patients that were IHC 3+ or IHC 2+/FISH positive, the “
strongly HER2-
positive
” group, exhibited the
greatest benefit from trastuzumab in the ToGA trial
03/28/2017
Bang et al; Lancet 2010